Raymond L. Woosley is an American pharmacologist who is the founding president and chairman of the board for AZCERT, a not-for-profit organization dedicated to improved outcomes from the use of medications.
C-Path is an independent, non-profit organization created by the U.S. Food and Drug Administration (FDA) and the University of Arizona to help launch the critical path initiative.
Woosley's research at Georgetown contributed substantially to the recognition that non-cardiovascular drugs, such as antihistamines (e.g., terfenadine (Seldane)), may have arrhythmogenic effects.
[5] Woosley's invention, fexofenadine (Allegra), resulted from this research and is today marketed as a safer non-sedating antihistamine replacing Seldane.
[8] He is an authority on drugs, like methadone, that prolong the QT interval on the electrocardiogram and cause a particular potentially lethal cardiac arrhythmia, torsade de pointes.
He has served on numerous advisory committees for the Food and Drug Administration, the National Institutes of Health, and the Department of Veterans Affairs.
He was the Sir Henry Hallet Dale Visiting Professorship in Clinical Pharmacology at the Johns Hopkins University School of Medicine.